Advances in multimodal immunotherapy have significantly reduced acute rejection rates and
substantially improved 1-year graft survival following renal transplantation. However, long …

Post‐transplant diabetes mellitus (PTDM) shows a relationship with risk factors including
obesity and tacrolimus‐based immunosuppression, which decreases pancreatic insulin …

A consensus meeting was held in Vienna on September 8–9, 2013, to discuss diagnostic
and therapeutic challenges surrounding development of diabetes mellitus after …

Heart transplantation is advocated in selected patients with advanced heart failure in the
absence of contraindications. Principal challenges in heart transplantation centre around an …

Immunosuppression strategies that selectively inhibit effector T cells while preserving and
even enhancing CD4+FOXP3+ regulatory T cells (Treg) permit immune self-regulation and …

Delayed graft function (DGF) remains a major barrier to improved outcomes after kidney
transplantation. High‐risk transplant recipients can be identified, but no definitive prediction …

B-cell depleting anti-CD20 monoclonal antibody therapies are being increasingly used as
long-term maintenance therapy for neuroinflammatory disease compared to many non …

Abstract Thymoglobulin (Thymoglobulin®; Genzyme, Cambridge, Mass., USA) is a
polyclonal antibody which has been used in the field of transplantation over the last four …

Glucocorticosteroids Induction and maintenance; acute cellular rejection and AMR Role in
maintenance immunosuppression under investigation because of severe side effects during …

Currently, kidney transplantation is the best treatment option for kidney failure for a majority
of eligible patients. It is associated with a better quality of life and reduced mortality as …